Listen
ACLASTA
-
Opinions on drugs -
Posted on
Jul 21 2010
- Updated on
Jan 18 2011
Reason for request
Renewal of inclusion on the list of medicines reimbursable by National Health Insurance at the same time as the renewal of inclusion of ZOMETA.
-
Clinical Benefit
| Substantial |
The transparency Committee considers that actual benefit of ACLASTA remains substantial in all of these indications. |
Contact Us
Évaluation des médicaments
